Business
PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
First patients enrolled on the Veris Cancer Care Platform NEW YORK, June 13, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a
About this update from Pavmed Inc.
[{"type":"text","content":"First patients enrolled on the Veris Cancer Care Platform\nNEW YORK, June 13, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) (\"PAVmed\" or the \"Company\") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. (\"Veris\"), today announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), a National Cancer Institute-Designated Comprehensive Cancer Center, launched a pilot program and enrolled the first patients on the Veris Cancer Care Platform™ pursuant to a recently-executed memorandum of understanding.\n\n \n \n \n \n \n \n\n \n\"The OSUCCC – James is one of the largest academic cancer centers in the nation and we couldn't be more excited to enroll our first patients in a pilot program at such a renowned institution at the forefront of cancer care,\" said James Mitchell, M.D., Veris' Chief Medical Officer. \"We look forward to completing a successful pilot program and continuing to execute our vision to offer enhanced personalized cancer care to the thousands of patients who receive systemic cancer therapy at the OSUCCC – James every year.\"\nThe Veris Cancer Care Platform is a comprehensive digital cancer care platform with remote physiological data collection, symptom reporting, telehealth capability, and electronic health record integration. The platform seeks to offer enhanced personalized cancer care through the early detection of complications, reduced unplanned hospitalizations, the provision of longitudinal trends of physiological and clinical data, data-driven risk management tools, and increased patient and provider satisfaction.\nCancer patients enrolled on the platform receive a VerisBox™ of Veris-branded connected health care devices which transmit physiologic data to the cloud-based clinician portal via embedded cellular connections. A complementary patient portal enables patients to report symptoms, as well as general health and quality of life parameters, to their cancer care team through the Veris patient smartphone app. The app also allows patients to invite caretakers and family members to follow along on their cancer care journey. Veris is also develop...